Ralph Brindis, a former president of the ACC, explained that as physicians became familiar with TAVR they grew interested in exploring off-label uses of the device.
The NCD itself was originally proposed by the ACC and STS in response to concerns over the potential problems and confusion that a disruptive new technology like TAVR could unleash.